Mutations involving oncogenesis and tumor suppressor genes are well known and reported in solid malignancies. Among these fusion genes are more commonly seen in hematologic malignancies than in solid tumors. One of the exceptions to this is Anaplastic Lymphoma Kinase (ALK, a receptor tyrosine kinase first identified as the product of a gene rearrangement in Anaplastic Large Cell Lymphoma. ALK has subsequently been found to be rearranged, mutated, or amplified in a further series of tumors including neuroblastoma, and Non-Small Cell Lung Cancer. Since last decade Kinase have become clinically validated targets for cancer therapy after the success story of Imatinib in Chronic Myeloid Leukemia. Since then Twelve small molecule kinase-targeting agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer. There is strong preclinical evidence that ALK is a driving force for oncogenesis and inhibition of ALK kinase activity results in anti-tumoural efficacy. These observations have sparked the development of several new small molecule kinase inhibitors, the most advanced of which got approved is crizotinib showing activity clinically in NSCLC patients. This manuscript provides a comprehensive review of ALK pathway, its inhibitors in clinical development, in particular crizotinib and future molecules.
INTRODUCTION
The current management strategies of cancer therapies like surgery, cytotoxic chemotherapy and radiotherapy, have limited utility in advanced stages. The recent evolution of systemic therapies in these stages paralleled the understanding of the tumorigenesis and better demonstration of the various cancer pathways. One among such pathways are protein kinases, which play an indispensable role in cellular signal transduction processes and regulate many aspects of the cell functions, including differentiation, growth and migration [1] . Deregulation of protein kinase, for example by amplification, translocation or mutation, is implicated in a number of serious diseases, including diabetes, inflammation and cancer. Thus, drugs that target abnormal kinase activity are very promising as potential targeted therapies. The current topic deals with one such target, anaplastic lymphoma kinase (ALK), an orphan receptor tyrosine kinase, first identified in patients with anaplastic large cell lymphomas (ALCL), as part of the t(2;5) chromosomal translocation [2] . With broader understanding of the ALK signaling [ALK gene at chromosomal band 2p23] and its varied partners [translocations] , its role now in various new tumors like neuroblastoma, and Non-Small Cell Lung Cancer, inflammatory myofibroblastic tumors and many more is getting established [3] . This manuscript provides a comprehensive review of ALK pathway, its role in *Address correspondence to this author at the Consultant Medical Oncologist & Hematologist, India; Tel: +91 9246 24 3034; E-mail: sureshattili@yahoo.com various tumors and drugs targeting the same at various levels of clinical development.
ALK STRUCTURE -FUNCTION IN PHYSIOLOGY AND PATHOLOGY
ALK is a receptor tyrosine kinase belonging to the Insulin Receptor super family. However its homology placed it among Lymphocyte Tyrosine Kinase making a discrete subfamily [4, 5] . Following the initial observation of ALK gene rearrangement in ALCL, the role of ALK in cancer pathogenesis has also emerged in several additional clinical settings. A variety of mechanisms leading to aberrant kinase activation and constitutive phosphorylation of downstream pathway components have been indentified, including miss sense mutation, gene amplification and chromosomal translocation. In the following sections we described these various activation mechanisms and the tumor types in which they have to date been described.
ALK Signaling in Cancer
In lines with other typical receptor pathways, leading to tyrosine kinase activation, the transforming potential of activated ALK is due to the aberrant phosphorylation of downstream substrates, which triggers deregulated intracellular signaling cascades. In cellular models the constitutive dimerisation of ALK-containing fusion proteins mediates the enhanced activation of three major pathways (Figure 1) • JAK-STAT3, [6] • PI3K-AKT and [7, 8] • RAS-MAPK pathways, [7, 8] These in turn will control cell proliferation and survival. ALK, by its varied rearrangements is known to have differential signaling in different tissues leading to a panorama of pathologies. Few of these important ones are discussed below.
Full-Length ALK -Point Mutations
Though exact role of wild-type ALK in pathogenesis is still debated, these point mutations are observed in a range of human malignant cell lines as well as tissue specimens of rhabdomyosarcoma, glioblastoma melanoma and more.
Rhabdomyosarcoma [RMS]
In view of RMS being one of the commonest curable pediatric malignancy, and extremely limited options are available at relapse, various alternative pathways, which could potentially be targeted, had been explored. The c-DNA library of Rh30 rhabdomyosarcoma cell line showed expression of ALK in a subset of rhabdomyosarcoma tumors [9, 10] . A genome-wide analysis confirmed ALK as target gene for PAX3-FKHR (the product of a recurring chromosomal translocation in alveolar variant) [11] , suggesting that further exploration of ALK as a new therapeutic opportunity for this indication is warranted. The early phase research showed significant activity of ALK inhibitors in RMS cell lines as well as animal models and the early phase human trials are on the way.
Glioblastoma
Though it is not a classical pediatric tumor and more often seen in adolescent group, it is of great interest as the therapeutic options after relapse are limited. In these tumors, ALK expression levels were found to correlate with those of its ligands, suggesting the possibility of an autocrine loop that putatively contributes to tumor proliferation. Among the well studied and proven pathways, truncated form of PTN and MK were found to promote proliferation in a glioblastoma cell line, [with activation of ALK and downstream signaling]. The combined targeting of ALK and PTN was shown to induced tumour growth inhibition in cell lines augmenting the hypothesis of this being a potential drug target [12] [13] [14] [15] .
Neuroblastoma
The involvement of full-length ALK in the pathogenesis of neuroblastoma, commonest pediatric solid tumor, is well documented. The prognosis of neuroblastoma is quite varied with few patients experiencing spontaneous regression, and remaining cases having rapid progression leading to metastatic phenotype and incurable despite aggressive therapeutic treatment [16] . Among these aggressive variants, ALK protein over expression was found both in primary neuroblastoma as well as metastatic sites, predominantly due to gene amplification. In addition to DNA amplification, other mechanisms like germline mutations in the tyrosine kinase domain of ALK may also have contributed by studies of Mosses et al. Viz. R1275Q mutation, in kinase activation Loop, the R1192P mutation at the beginning of the b4 strand of the kinase domain and few others [17] [18] [19] [20] [21] . The preclinical studies have demonstrated considerable antitumor activity of the ALK inhibitors in cell lines and further studies are ongoing.
Other Neural Disorders
In view of the identification of ALK being significant in two important neural tumors [GBM and Neuroblastoma], a thorough evaluation of the distribution of ALK expression in normal tissues was performed, which demonstrated ALK expression in specific area of mouse brain during development, with a strong signal detected from day 11 pc in thalamus, hypothalamus, mid-brain, dorsal root ganglia and olfactory bulb. The restricted expression pattern of ALK mRNA in murine and human tissues suggests that this receptor tyrosine kinase might play an important role in development and function of the nervous system. Recent studies, have provided evidence that ALK mediates PTN-stimulated neurite outgrowth during embryonic development, and regeneration of damaged motor neurons in the adult. This has been suggested to be of possible therapeutic interest for conditions involving motor neuron/axon damage [22, 23] .
Similarly, hippocampal neurogenesis, which is linked to regulation of mood, learning and memory processes, it is being studied in subjects with chronic treatment with antidepressants especially for mood disorders. These findings are important as we may anticipate side effects involving the mood while using ALK inhibitors. Similarly, the same could be explored optimally for therapeutic benefits in various neuropsychiatric disorders.
Anaplastic Large Cell Lymphoma [ALCL]
It is an important tumor, not because ALK was first identified but it forms an ideal model for the prognostic and predictive model for the ALK. The observations that ALK expression is associated with good prognosis in the patients treated with CHOP [>80% remission vs. <35% in ALK negative tumors] lead to routine use of this marker in ALCL. However the ALK expression is not a mandate/ diagnostic criteria in this rare type of Tcell lymphoma [2.5-5%, mostly children and adolescents]. The diagnosis mainly relies on histopathological demonstration of heterogeneous cellular entities, characterized by large cells with a variable shape (anaplastic pattern), invariably expressing CD30 [24] and not other T cell markers (thought to be lost during tumor evolution) [24] .
Inflammatory Myofibroblastic Tumour (IMT)
An uncommon, not yet clearly defined disorder, fits as bridging disease from locally aggressive disorder vs. inflammation is now thought to be a neoplasm based on the observation of Chromosomal rearrangements involving the 2p23 locus, which further encode ALK fusion proteins [25, 26] . These tumors are of mesenchymal origin and are composed of neoplastic spindle cells mixed with a reactive inflammatory infiltrate of lymphocytes and plasma cells. After the initial identification of TPM3-ALK and TPM4-ALK chimeric proteins in three IMT patients in 1999, a series of additional fusion proteins were detected including CARS-ALK, CLTC-ALK, ATIC-ALK, RANBP2-ALK, SEC31LB-ALK [25] [26] [27] [28] . With the exception of RANPB2-ALK, which is localized to the nuclear membrane, all the other fusion proteins display a typical cytoplasmic staining. The expression of ALK was generally found in younger patients and correlated with local recurrence rather than with distant metastasis formation. These observations suggest that ALK targeted therapy could be useful in patients with ALK positive, recurrent IMTs.
Non-Small Cell Lung Cancer (NSCLC)
Though not a pediatric tumor, NSCLC forms a classical model to study the drug development. ALK in NSCLC, is a gene rearrangement involving an inversion within the short arm of chromosome 2 (between loci 2p21 and 2p23), leading to expression of an oncogenic protein containing the N-terminal portion of echinoderm microtubule associated protein like 4 (EML4) and the entire intracellular portion of ALK. This EML4-ALK is to date by far the most frequent and best characterized ALK gene rearrangement and widely targeted. After this characterization in a small subset (6-7%) of NSCLC patients, the breakthrough came in 2007 with invention of Crezotinib and unambiguous evidence of prolongation of survival in patients with advanced tumors [29] .
Other Tumours with ALK Gene Rearrangement
CLTC-ALK and NPM-ALK fusion proteins were identified in a rare, but aggressive phenotype of B-cell Non-Hodgkin Lymphoma [30] with t(2;17)(p23;q23) translocation. Similarly, TPM4-ALK was found expressed in esophageal squamous cell carcinoma in an Iranian as well as Chinese population [31] . Systemic histiocytosis was also found to have, ALK fusion proteins though additional validation data are required [32] .
ALK Small Molecule Inhibitors-Approved Drugs and Clinical Pipeline
Unlike the other TKIs, the evolution of molecules targeting ALK had been significantly lagged because of various reasons including non uniform protein derivatives and the ambiguity of its role in oncogenesis. However the recent research, which focused on most proven site of path way i.e. ATP binding site of kinase, found some good candidates, assuming homology models, which are described in Table 2 . Crizotinib, the prototype drug in this category, and the only one with regulatory approval started its course with 50 mg and escalated till 300 in various cohorts and the 250 mg twice a day dose was defined on molecular based cohorting approaches. This has lead to two phase II studies and a phase III study, which showed that the drug is effective in all ALK mutated patients and had a median overall survival of approximately 90% at the end of 6 months and 81% at the end of 12 months. The later studies showed overall Response rates of 61% and a median progression free survival of 10 months. The most frequent adverse events observed with crizotinib were mild and moderate gastrointestinal events and mild visual disturbances and is very well tolerated. CONCLUSIONS ALK, one of the earlier identified and most atypical genes is proven to be associated with oncogenesis in a spectrum of solid tumors like Non small cell lung cancer and more recently in other tumor types like Rhabdomyosarcoma, Neuroblastoma, ALCL, IMT and many more. Various partner genes for ALK were also identified and their roles were also proven as described in Table 1 . Though non uniform protein derivatives of ALK and the ambiguity of its role in oncogenesis led to a delay in drug development of this pathway, the recent approval of crizotinib and dozens of molecule in pipeline is making future optimistic in various tumors like Rhabdomyosarcoma Glioblastoma Multiform etc. 
